Sucampo Pharma (SCMP) Tops Q4 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sucampo Reports Continued Strong Performance for Fourth Quarter and Full Year 2015
March 8, 2016 6:30 AM ESTResults Driven by Continued AMITIZA Growth and R-TECH UENO Acquisition
Company Reiterates 2016 Guidance
Company to Host Conference Call Today at 8:30 a.m. EST
ROCKVILLE, Md., March 08, 2016 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ: SCMP), a global biopharmaceutical company, today reported consolidated financial results for the fourth quarter and full year ended December 31, 2015. Financial results include consolidated operations from R-Tech Ueno as of October 21, 2015.
... More